8-K: Tarsus Pharmaceuticals Secures $200 Million Non-Dilutive Financing to Refinance Debt and Support Growth

Tarsus Pharmaceuticals has secured a $200 million non-dilutive financing commitment from Pharmakon Advisors, refinancing existing debt and providing capital for general corporate purposes.

Summary

• Tarsus Pharmaceuticals has entered into a loan agreement with Pharmakon Advisors for a total of $200 million.
• The initial tranche of $75 million was funded on April 19, 2024, and was used to repay existing debt with Hercules Capital and Silicon Valley Bank, cover transaction costs, and for general corporate purposes.
• The remaining $125 million is available in three additional tranches of $25 million, $50 million, and $50 million, subject to certain conditions and milestones.
• The loan matures on April 19, 2029, and bears interest at a floating rate based on the 90-day average secured overnight financing rate (SOFR) plus a margin of 6.75% per annum, with a 3.75% floor on SOFR.
• The loan is non-dilutive, meaning Tarsus is not required to issue warrants to the lenders.
• The agreement includes customary covenants, but no financial covenants, and is secured by a lien on substantially all of Tarsus' assets.
• Net proceeds to the company at closing were approximately $40 million after repaying existing debt and covering fees.

Sentiment

Score: 8

Explanation: The document indicates a positive development for Tarsus, securing a significant amount of non-dilutive financing and refinancing existing debt. The absence of financial covenants and the option for additional tranches are also positive. However, the floating interest rate and security on assets introduce some risk.

Positives

• The $200 million financing strengthens Tarsus' financial position.
• The financing is non-dilutive, avoiding shareholder dilution.
• The loan has no financial covenants, providing operational flexibility.
• The company has access to additional capital through three optional tranches.
• The refinancing replaces existing debt with a new five-year interest-only facility.

Negatives

• The loan is secured by a lien on substantially all of Tarsus' assets.
• The company is required to prepay the loan in full upon a change of control.
• Prepayments are subject to customary make-whole and prepayment premiums.
• The loan bears a floating interest rate, exposing Tarsus to potential rate increases.

Risks

• The floating interest rate exposes the company to potential increases in borrowing costs.
• The company is required to prepay the loan in full upon a change of control, which could be costly.
• Failure to meet the conditions for the additional tranches could limit access to further funding.
• The loan is secured by a lien on substantially all of Tarsus' assets, which could impact future financing options.

Future Outlook

Tarsus expects the financing to provide financial flexibility and support future business development. The company has the option to draw additional tranches of the loan, subject to certain conditions and milestones.

Management Comments

• Tarsus has secured $200 million in committed capital from funds associated with Pharmakon Advisors, LP.
• Tarsus has elected to draw $75 million on the closing date, April 19, 2024.
• The new five-year interest-only credit facility with Pharmakon provides for three potential additional loan tranches.

Industry Context

This financing is a common strategy for biotech companies to secure non-dilutive capital to fund operations and growth, particularly for companies with approved products and ongoing clinical trials. Pharmakon Advisors is a well-known investor in the life sciences industry, indicating confidence in Tarsus' prospects.

Comparison to Industry Standards

• The use of a floating rate loan based on SOFR plus a margin is a standard practice in the life sciences debt financing market.
• The absence of financial covenants is favorable for Tarsus, providing more operational flexibility compared to some other debt agreements.
• The non-dilutive nature of the financing is a positive for existing shareholders, as it avoids dilution of their ownership.
• Pharmakon Advisors' involvement, with a history of $7.8 billion in commitments across 51 investments, suggests a strong level of institutional support for Tarsus.
• Comparable companies in the biotech space often use similar debt financing structures to fund operations and clinical trials, such as companies like Biohaven or Neurocrine Biosciences, which have also secured non-dilutive debt financing.

Stakeholder Impact

• Shareholders benefit from the non-dilutive nature of the financing.
• Employees benefit from the increased financial stability of the company.
• Customers and patients may benefit from the continued development of Tarsus' pipeline.
• Creditors benefit from the repayment of existing debt.

Next Steps

• Tarsus will file the full Loan Agreement as an exhibit to its Quarterly Report on Form 10-Q for the period ending June 30, 2024.
• Tarsus may draw on the additional loan tranches subject to certain conditions and milestones.
• Tarsus will continue to advance its pipeline of therapeutic candidates.

Key Dates

Keywords

financing, debt, loan, non-dilutive, Pharmakon Advisors, Tarsus Pharmaceuticals, refinancing, SOFR, credit facility